Losartan Potassium and Hydrochlorothiazide Tablets USP, 100 mg/12.5 mg a) 30-count bottles (NDC# 68180-216-06) b) 90-count bottles (NDC# 68180-216-09), Rx Only, Manufactured By: Lupin Limited, Pithampur, India, MFG For: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, USA
Publicado el 11 de mayo de 2022 · Inicio del retiro: 31 de marzo de 2022
Resumen
FDA registra el retiro D-0843-2022 de medicamentos de Clase II, publicado el 11 de mayo de 2022 e iniciado el 31 de marzo de 2022. Empresa responsable: Lupin Pharmaceuticals Inc.; Estado: Finalizado; Cantidad reportada: 2,361,924 bottles; Lote: Lot # H001878 6/30/2022 68180-216-06 H002178 7/31/2022 68180-216-06 H002626 9/30/2022 68180-216-06 H102149 9/30/2023 68180-216-06 H001600 5/31/2022 68180-216-09 H001601 5/1/2022 68180-216-09 H001625 5/31/2022 68180-216-09 H001626 5/31/2022 68180-216-09 H001794 6/30/2022 68180-216-09 H001795 6/30/2022 68180-216-09 H001796 6/30/2022 68180-216-09 H001797 6/30/2022 68180-216-09 H001879 6/30/2022 68180-216-09 H001880 6/30/2022 68180-216-09 H001881 6/30/2022 68180-216-09 H001942 6/30/2022 68180-216-09 H001943 6/30/2022 68180-216-09 H001944 6/30/2022 68180-216-09 H001945 6/30/2022 68180-216-09 H001946 6/30/2022 68180-216-09 H002179 7/31/2022 68180-216-09 H002180 7/31/2022 68180-216-09 H002181 8/31/2022 68180-216-09 H002182 8/31/2022 68180-216-09 H002183 8/31/2022 68180-216-09 H002237 8/31/2022 68180-216-09 H002238 8/31/2022 68180-216-09 H002239 8/31/2022 68180-216-09 H002240 8/31/2022 68180-216-09 H002241 8/31/2022 68180-216-09 H002627 9/30/2022 68180-216-09 H002628 9/30/2022 68180-216-09 H002629 9/30/2022 68180-216-09 H002630 9/30/2022 68180-216-09 H002631 9/30/2022 68180-216-09 H002979 11/30/2022 68180-216-09 H002980 11/30/2022 68180-216-09 H002981 11/30/2022 68180-216-09 H002982 11/30/2022 68180-216-09 H002983 11/30/2022 68180-216-09 H100112 12/31/2022 68180-216-09 H100113 12/31/2022 68180-216-09 H100114 12/31/2022 68180-216-09 H100115 12/31/2022 68180-216-09 H100116 12/31/2022 68180-216-09 H100156 12/31/2022 68180-216-09 H100157 12/31/2022 68180-216-09 H100622 2/28/2023 68180-216-09 H100623 2/28/2023 68180-216-09 H100624 2/28/2023 68180-216-09 H100625 2/28/2023 68180-216-09 H100626 2/28/2023 68180-216-09 H100627 2/28/2023 68180-216-09 H100628 2/28/2023 68180-216-09 H100629 2/28/2023 68180-216-09 H100939 4/30/2023 68180-216-09 H100940 4/30/2023 68180-216-09 H100941 4/30/2023 68180-216-09 H100942 4/30/2023 68180-216-09 H100943 4/30/2023 68180-216-09 H101094 5/31/2023 68180-216-09 H101095 5/31/2023 68180-216-09 H101096 5/31/2023 68180-216-09 H101097 5/31/2023 68180-216-09 H101098 5/31/2023 68180-216-09 H101151 5/31/2023 68180-216-09 H101152 5/31/2023 68180-216-09 H101290 5/31/2023 68180-216-09 H101291 5/31/2023 68180-216-09 H101292 5/31/2023 68180-216-09 H101293 5/31/2023 68180-216-09 H101323 5/31/2023 68180-216-09 H101324 5/31/2023 68180-216-09 H101823 7/31/2023 68180-216-09 H101824 7/31/2023 68180-216-09 H101825 7/31/2023 68180-216-09 H101853 8/31/2023 68180-216-09 H101854 8/31/2023 68180-216-09 H101855 8/31/2023 68180-216-09 H101856 8/31/2023 68180-216-09 H102127 9/30/2023 68180-216-09 H102128 9/30/2023 68180-216-09 H102129 9/30/2023 68180-216-09 H102130 9/30/2023 68180-216-09 H102150 9/30/2023 68180-216-09 H102151 9/30/2023 68180-216-09 H102152 9/30/2023 68180-216-09 H102153 9/30/2023 68180-216-09 H102154 9/30/2023 68180-216-09 H102155 9/30/2023 68180-216-09 H102201 9/30/2023 68180-216-09 H102223 9/30/2023 68180-216-09 H102268 9/30/2023 68180-216-09 H102269 9/30/2023 68180-216-09 H102270 9/30/2023 68180-216-09 H102271 9/30/2023 68180-216-09. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Marca
- LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Fabricante
- Lupin Pharmaceuticals Inc.
- Distribuidor
- Product was distributed nationwide
- UPC
- 0368180215066
- Lote
- Lot # H001878 6/30/2022 68180-216-06 H002178 7/31/2022 68180-216-06 H002626 9/30/2022 68180-216-06 H102149 9/30/2023 68180-216-06 H001600 5/31/2022 68180-216-09 H001601 5/1/2022 68180-216-09 H001625 5/31/2022 68180-216-09 H001626 5/31/2022 68180-216-09 H001794 6/30/2022 68180-216-09 H001795 6/30/2022 68180-216-09 H001796 6/30/2022 68180-216-09 H001797 6/30/2022 68180-216-09 H001879 6/30/2022 68180-216-09 H001880 6/30/2022 68180-216-09 H001881 6/30/2022 68180-216-09 H001942 6/30/2022 68180-216-09 H001943 6/30/2022 68180-216-09 H001944 6/30/2022 68180-216-09 H001945 6/30/2022 68180-216-09 H001946 6/30/2022 68180-216-09 H002179 7/31/2022 68180-216-09 H002180 7/31/2022 68180-216-09 H002181 8/31/2022 68180-216-09 H002182 8/31/2022 68180-216-09 H002183 8/31/2022 68180-216-09 H002237 8/31/2022 68180-216-09 H002238 8/31/2022 68180-216-09 H002239 8/31/2022 68180-216-09 H002240 8/31/2022 68180-216-09 H002241 8/31/2022 68180-216-09 H002627 9/30/2022 68180-216-09 H002628 9/30/2022 68180-216-09 H002629 9/30/2022 68180-216-09 H002630 9/30/2022 68180-216-09 H002631 9/30/2022 68180-216-09 H002979 11/30/2022 68180-216-09 H002980 11/30/2022 68180-216-09 H002981 11/30/2022 68180-216-09 H002982 11/30/2022 68180-216-09 H002983 11/30/2022 68180-216-09 H100112 12/31/2022 68180-216-09 H100113 12/31/2022 68180-216-09 H100114 12/31/2022 68180-216-09 H100115 12/31/2022 68180-216-09 H100116 12/31/2022 68180-216-09 H100156 12/31/2022 68180-216-09 H100157 12/31/2022 68180-216-09 H100622 2/28/2023 68180-216-09 H100623 2/28/2023 68180-216-09 H100624 2/28/2023 68180-216-09 H100625 2/28/2023 68180-216-09 H100626 2/28/2023 68180-216-09 H100627 2/28/2023 68180-216-09 H100628 2/28/2023 68180-216-09 H100629 2/28/2023 68180-216-09 H100939 4/30/2023 68180-216-09 H100940 4/30/2023 68180-216-09 H100941 4/30/2023 68180-216-09 H100942 4/30/2023 68180-216-09 H100943 4/30/2023 68180-216-09 H101094 5/31/2023 68180-216-09 H101095 5/31/2023 68180-216-09 H101096 5/31/2023 68180-216-09 H101097 5/31/2023 68180-216-09 H101098 5/31/2023 68180-216-09 H101151 5/31/2023 68180-216-09 H101152 5/31/2023 68180-216-09 H101290 5/31/2023 68180-216-09 H101291 5/31/2023 68180-216-09 H101292 5/31/2023 68180-216-09 H101293 5/31/2023 68180-216-09 H101323 5/31/2023 68180-216-09 H101324 5/31/2023 68180-216-09 H101823 7/31/2023 68180-216-09 H101824 7/31/2023 68180-216-09 H101825 7/31/2023 68180-216-09 H101853 8/31/2023 68180-216-09 H101854 8/31/2023 68180-216-09 H101855 8/31/2023 68180-216-09 H101856 8/31/2023 68180-216-09 H102127 9/30/2023 68180-216-09 H102128 9/30/2023 68180-216-09 H102129 9/30/2023 68180-216-09 H102130 9/30/2023 68180-216-09 H102150 9/30/2023 68180-216-09 H102151 9/30/2023 68180-216-09 H102152 9/30/2023 68180-216-09 H102153 9/30/2023 68180-216-09 H102154 9/30/2023 68180-216-09 H102155 9/30/2023 68180-216-09 H102201 9/30/2023 68180-216-09 H102223 9/30/2023 68180-216-09 H102268 9/30/2023 68180-216-09 H102269 9/30/2023 68180-216-09 H102270 9/30/2023 68180-216-09 H102271 9/30/2023 68180-216-09
- Clasificación de riesgo
- Class II
- Área (FDA)
- drug
- País
- United States
Retiros relacionados
- FDALosartan Potassium and Hydrochlorothiazide Tablets, USP 50mg /12.5 mg, 1000-count bottle, Rx only,22 de mayo de 2024
- FDALosartan potassium & Hydrochlorothiazide Tablets 100 mg/25 mg, 30, 90 & 1000 count NDC # 33342-052-07, NDC6 de julio de 2022
- FDALosartan Pot./HCTZ 100/12.5 mg Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 Mfg For: Lupin8 de junio de 2022
- FDALosartan Pot/HCTZ 50/12.5 mg 90 Tabs NDC 72189-297-90 Packaged and Distributed By: Direct Rx Dawsonville, GA1 de junio de 2022
- FDALosartan Potassium and Hydrochlorothiazide Tablets USP, 100 mg/25 mg a) 30-count bottles (NDC# 68180-217-06)11 de mayo de 2022
- FDAalprazolam XR extended-release tablets, 3 mg, 60-count bottle, Rx only, Distributed by: Greenstone LLC,11 de mayo de 2022
Preguntas sobre este retiro
¿Losartan Potassium and Hydrochlorothiazide Tablets USP, 100 mg/12.5 mg a) 30-count bottles (NDC# 68180-216-06) b) 90-count bottles (NDC# 68180-216-09), Rx Only, Manufactured By: Lupin Limited, Pithampur, India, MFG For: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, USA fue retirado del mercado?
Sí. FDA publicó el retiro D-0843-2022 el 11 de mayo de 2022. Peligro reportado: CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter
¿Cómo sé si mi unidad está incluida en el retiro?
Compara los datos de tu producto con los del aviso. Marca: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE. UPC: 0368180215066.